The group’s determination to conquer another rare epilepsy, tuberous sclerosis complex, looks questionable.
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
The first quarter of 2021 saw fewer deals than any in recent memory.
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
It's official: dramatic share price jumps in response to clinical data have become more common.